Key words: Asthma, Omalizumab, Severe asthma, Anti-IgE effect, Children
The percentage of asthmatic children with severe asthma is low (< 5%). Children with severe
asthma require treatment with high dose of inhaled steroids plus a second controller
and/or systemic steroids to control symptoms. They can also remain uncontrolled despite
these therapies. Adherence to therapy must always be controlled, especially in case of
poor response to therapy and uncontrolled symptoms. Omalizumab is a monoclonal antibody
with an anti-IgE effect that could work successfully to control symptoms in selected
children with severe asthma. Asthma guidelines consider omalizumab as last therapeutic
step in asthmatic children. The paper describes the case of a female paediatric patient
with severe asthma treated with omalizumab who had clinical benefits from it and whose
medications were gradually reduced and then stopped.
Vuoi citare questo contributo?
L'accesso è riservato agli abbonati
alla rivista che si siano registrati.
Per accedere all'articolo in formato full text è necessario inserire username e password.
L'immissione di nuovi contenuti è riservata ai soli utenti registrati